iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
150 hedge funds and large institutions have $373M invested in iTeos Therapeutics in 2024 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 43 reducing their positions, and 12 closing their positions.
585% more call options, than puts
Call options by funds: $27M | Put options by funds: $3.94M
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
33% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 43
9% more funds holding
Funds holding: 137 → 150 (+13)
0.03% more ownership
Funds ownership: 100.13% → 100.16% (+0.03%)
30% less capital invested
Capital invested by funds: $537M → $373M (-$163M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$36.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.22M |
| 3 |
6CM
683 Capital Management
New York
|
+$6.95M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$4.83M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$25M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$11.1M |
| 3 |
DM
Deerfield Management
New York
|
-$10.7M |
| 4 |
Morgan Stanley
New York
|
-$8.97M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Los Angeles Capital Management
Los Angeles,
California
| – | -$377K | -25,398 | Closed |
|
152
Group One Trading
Chicago,
Illinois
| – | -$358K | -23,439 | Closed |
|
|
YIH
153
Y-Intercept (HK)
Hong Kong
| – | -$309K | -20,814 | Closed |
|
|
CM
154
Caption Management
Oklahoma City,
Oklahoma
| – | -$290K | -19,000 | Closed |
|
155
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$249K | -16,485 | Closed |
|
156
Simplex Trading
Chicago,
Illinois
| – | -$245K | -16,083 | Closed |
|
|
CIC
157
Cornercap Investment Counsel
Atlanta,
Georgia
| – | -$195K | -13,119 | Closed |
|
158
Allspring Global Investments
Charlotte,
North Carolina
| – | -$56K | -3,776 | Closed |
|
159
Pacer Advisors
Malvern,
Pennsylvania
| – | -$3.04K | -205 | Closed |
|
ITOS Hedge Fund Activity: Q3 2024 in Review
150 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q3 2024, worth a combined $373M — down 30% from $537M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ITOS positions and 12 closed out — a net gain of 13 holders — while 57 added to existing stakes and 43 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $36.7M. The largest seller was EcoR1 Capital, cutting an estimated $25M.
- 150 institutional investors held iTeos Therapeutics (ITOS) as of Q3 2024, up from 137 in Q2 2024.
- Funds reported $373M of iTeos Therapeutics stock for Q3 2024, down 30% quarter-over-quarter.
- 25 funds opened new iTeos Therapeutics positions in Q3 2024 and 12 closed out, a net change of +13 holders.
- The largest iTeos Therapeutics buyer in Q3 2024 was Tang Capital Management, an estimated $36.7M added.
- The largest iTeos Therapeutics seller in Q3 2024 was EcoR1 Capital, an estimated $25M sold.
Based on aggregated 13F filings for Q3 2024.